A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of OS, according to the agents’ manufacturerTiragolumab (Genentech/Roche) is an immunotherapy designed to bind to TIGIT, a protein receptor on immune cells. Atezolizumab (Tecentriq, Genentech/Roche) is an anti-PD-L1 therapy.
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.
Clinical trial criteria excluded a significant number of adults without diabetes eligible for GLP-1 receptor agonist treatment from studies assessing the drugs’ safety and efficacy,…
Exposure to per- and polyfluoroalkyl substances may be linked to worse kidney function by reduced short-chain fatty acid-producing bacteria and anti-inflammatory metabolites, according to a…
Drug overdose deaths decreased slightly in 2023 compared with the previous year but still remain at a near-historic high, according to an AMA report.The slim…
Young adolescents who used cannabis more frequently reportedpsychosis spectrum symptoms and greater distress from such symptoms, according to results of a cohort study published in…
Some diabetes medications could help reduce alcohol consumption and alcohol-related health problems, particularly in those with obesity, results of a systematic review published in eClinicalMedicine…
Honoring five extraordinary nurses who inspire and uplift the Moffitt community
PHILADELPHIA (November 20, 2024) — Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program and member of the Cancer Epigenetics…
The SABR UK consortium’s official BlueSky account. Please follow us and share our BlueSky page! https://bsky.app/profile/uksabr.bsky.social
China’s NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.
